HELP Cybin Inc.
Company Analysis
Latest News
🟢 Cybin is trading 10.2% up today despite broader market losses
Cybin is trading 10.2% up at $13.65, despite the S&P 500, Nasdaq Composite, and Dow Jones all trading lower; the specific catalyst remains unconfirmed. - On...
🟢 Cybin is trading 5.65% up today despite broader market weakness
Cybin is trading 5.65% up at $13.09, based on live price context; no confirmed catalyst is identified. - On September 9, 2026, the S&P 500, Nasdaq, and Dow...
🔴 Cybin is trading 5.3% down today amid growth-oriented biotech weakness
Cybin is trading at $11.54, down 5.30%, during the August 31, 2026 session amid weakness across growth-oriented biotech stocks. - No clear company-specific...
🔴 Cybin is trading 5.2% down today amid broad biotech-sector weakness
Cybin is trading 5.21% down at $12.55, with the decline appearing mainly tied to biotech-sector weakness. - XBI is down 2.31% as investors reduce exposure to...
🟢 Cybin is trading 5.8% up today as biotech sector gains 2.06%
Cybin is trading at $13.78, up +5.80%, after the biotechnology sector gained 2.06% during the regular session. - No fresh company-specific announcement or...
Cybin Secures Buy Ratings, TD Cowen Hikes Price Target to $62
Cybin Inc. currently maintains an average "Buy" rating from five research firms. TD Cowen recently increased its price target for the stock from $8.00 to...
🟢 Cybin is trading 5% up today on positive mRNA cancer-vaccine trial news
Cybin is trading up 5.35% now at $12.41, as biotechnology shares rally broadly on positive mRNA cancer-vaccine trial news. - No fresh company-specific...
🟢 Cybin is trading 10.8% up today ahead of August 12, 2026 earnings
Cybin is trading 10.8% up at $11.18 as investors position ahead of the company’s expected August 12, 2026 earnings release and CEO Michael Halstead’s same-day...
Cybin Surges 10.7% Ahead of Earnings — Can a Depression Drug With No Revenue Justify a $700 Million Bet?
Shares of Cybin Inc., now operating as Helus Pharma, jumped 10.7% to $11.17 on August 12 as investors piled in ahead of the company's fiscal second-quarter...
🟢 Helus Pharma (Cybin) trading up 10.69% in pre-market ahead of CEO's fireside chat at Canaccord Genuity Growth Conference
Helus Pharma, operating as Cybin, is trading 10.69% up at $11.17 as investors anticipate CEO Michael Halstead's fireside chat today, August 12, 2026. Halstead...
Cybin Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 12, 2026
For the fiscal quarter ending June 30, 2026, Cybin Inc. is expected to report a consensus EPS loss of -$0.80 on zero revenue, with shares currently trading at...
🔴 Cybin is trading 10.34% down today after profit-taking reversed part of its recent rally
Cybin is trading 10.34% down now at $10.41 after profit-taking reversed part of its recent rally. - Opening-day selling reversed part of the advance from...
🔴 Cybin is trading 7.75% down today after selling reversed part of recent rally
Cybin is trading 7.75% down now at $10.61 after opening-day selling reversed part of a sharp recent rally. - Shares climbed from $7.82 on July 31, 2026, to...
Cybin Taps a $14.6 Billion Dealmaker as CEO — But Can One Hire Bridge the Gap Between Clinical Promise and Commercial Reality?
Shares of Cybin Inc. (HELP) surged as much as 13% this week after the clinical-stage psychedelic-medicine company, now operating as Helus Pharma, announced it...
🟢 Cybin is trading 7.6% up today after Michael Halstead became CEO
Cybin is trading 7.6% up at $11.33, extending gains after Michael Halstead became chief executive officer effective immediately. - Halstead previously led...
🟢 Cybin is trading 10.1% up today as investors extend CEO appointment rally
Cybin is trading 10.1% up today at $10.22 as the stock continues to rally following the appointment of former Intra-Cellular Therapies president Michael...
🟢 Cybin is trading 11% up today after appointing former Intra-Cellular president Michael Halstead as CEO
Cybin is trading 11% up at $8.88 following the announcement of Michael Halstead as its new CEO. • Halstead previously served as the president of...
Cybin Names Michael Halstead CEO, Architect of $14.6B J&J Deal
Cybin Inc., operating as Helus Pharma (Nasdaq: HELP), appointed Michael Halstead as Chief Executive Officer, effective immediately. Halstead previously served...
Wells Fargo initiates Helus Pharma at overweight, citing depression drug potential
Wells Fargo initiated coverage of Helus Pharma (HELP) with an Overweight rating. The bank set a $16 price target for the biotechnology firm. This target...
🟢 Cybin is trading 10.2% up today amid a broad risk-on market rally
Cybin is trading at $8.40 (+10.24%) in pre-market as higher-beta names benefit from a broad risk-on move across U.S. markets. • The stock is tracking a wider...